WO2006082842A1 - Gélule dure de solubilité améliorée - Google Patents

Gélule dure de solubilité améliorée Download PDF

Info

Publication number
WO2006082842A1
WO2006082842A1 PCT/JP2006/301645 JP2006301645W WO2006082842A1 WO 2006082842 A1 WO2006082842 A1 WO 2006082842A1 JP 2006301645 W JP2006301645 W JP 2006301645W WO 2006082842 A1 WO2006082842 A1 WO 2006082842A1
Authority
WO
WIPO (PCT)
Prior art keywords
capsule
hard
pullulan
weight
hard capsule
Prior art date
Application number
PCT/JP2006/301645
Other languages
English (en)
Japanese (ja)
Inventor
Satoshi Sakuma
Original Assignee
Qualicaps Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Qualicaps Co., Ltd. filed Critical Qualicaps Co., Ltd.
Priority to JP2007501586A priority Critical patent/JPWO2006082842A1/ja
Publication of WO2006082842A1 publication Critical patent/WO2006082842A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/20—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
    • A23L29/206—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin
    • A23L29/256—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin from seaweeds, e.g. alginates, agar or carrageenan
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/20—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
    • A23L29/206—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin
    • A23L29/262—Cellulose; Derivatives thereof, e.g. ethers
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/20—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
    • A23L29/269—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of microbial origin, e.g. xanthan or dextran
    • A23L29/274—Pullulan
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/30—Foods or foodstuffs containing additives; Preparation or treatment thereof containing carbohydrate syrups; containing sugars; containing sugar alcohols, e.g. xylitol; containing starch hydrolysates, e.g. dextrin
    • A23L29/37—Sugar alcohols
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
    • A23P10/00—Shaping or working of foodstuffs characterised by the products
    • A23P10/30—Encapsulation of particles, e.g. foodstuff additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol

Definitions

  • the present invention relates to a hard capsule comprising a water-soluble cellulose ether or pullulan as a main component of a capsule skin, wherein a sugar alcohol is blended in the capsule skin, a method for producing the hard capsule, and
  • the present invention relates to a hard capsule in which the hard capsule is filled.
  • Gelatin hard capsules are widely used as capsules for filling medicines, foods, and health foods.
  • the medicine filled in the capsule is susceptible to hydrolysis, the capsule skin retains about 15% of water, so the medicine decomposes and the potency of the active ingredient Deterioration, deterioration, and discoloration may occur. Also, it may cause inconveniences such as insolubility of gelatin hard capsule film.
  • gelatin used as a hard capsule base is an animal protein.
  • gelatin capsule that replaces the gelatin capsule in view of the risk of mad cow disease infection. Yes.
  • Patent Document 1 As an alternative to the gelatin hard capsule, for example, hard capsules based on water-soluble cellulose ethers are known (Patent Document 1, Patent Document 2, Patent Document 3). A hard capsule using a pullulan polysaccharide as a capsule base has also been reported (Patent Document 4). Hard capsules based on these water-soluble cellulose ethers and pullulan have excellent characteristics such as low moisture content and resistance to cracking and less insolubilization over time compared to normal gelatin capsules. is doing. However, there was a problem that the dissolution was slightly delayed compared to hard gelatin capsules. These Patent Documents 1 to 4 disclose that the elution property of capsule is improved.
  • Patent Document 5 discloses that a water-soluble substance (saccharide) is added to the shell of a gelatin capsule to improve the solubility of the capsule.
  • a large amount of 101-200 parts by weight of water-soluble substance (saccharide) must be added to 100 parts by weight of gelatin. There is a concern that the capsule strength may decrease.
  • capsules based on water-soluble cellulose ethers and pullulan have been disclosed!
  • Patent Documents 6 to 8 are described as capsules in which saccharides are blended in capsule skins. However, there is a difference in soft capsules whose physical properties are significantly different from hard capsules. Disclosed are hard capsules based on water-soluble cellulose ethers and pullulan.
  • the above known hard capsules and soft capsules are not practical capsules in view of elution, moldability, stability, quality, etc., which are difficult to industrially mass produce.
  • Patent Document 1 Japanese Patent Application Laid-Open No. 2000-136126
  • Patent Document 2 JP-A-8-208458
  • Patent Document 3 Japanese Patent No. 2552937
  • Patent Document 4 Special Table 2003-505565 (WO01 / 007507) Publication
  • Patent Document 5 Japanese Patent Laid-Open No. 9-202727
  • Patent Document 6 Japanese Unexamined Patent Application Publication No. 2004-167084
  • Patent Document 7 Japanese National Patent Publication No. 8-511795 (WO95 / 00123)
  • Patent Document 8 Special Table 2001—505925 (W098 / 42316)
  • Gelatin hard capsules are commonly used as hard capsules for pharmaceuticals, foods, health foods, and the like.
  • gelatin frequently used as a hard capsule base is an animal protein, and there is a risk of mad cow disease infection which has become a problem in recent years.
  • Gelatin hard capsules also have an undesirable phenomenon of insolubility due to changes over time.
  • water-soluble cellulose ethers or hard capsules based on the polysaccharide pullulan have been developed. There remains room for improvement in their dissolution and moldability. It was.
  • a water-soluble cellulose agent As a result of intensive studies to solve the above-mentioned problems, the present inventors have found that a water-soluble cellulose agent. It has been found that the solubility of water-soluble cellulose ethers or pullulan capsules can be improved by adding sugar alcohols, preferably monosaccharide alcohols, to hard capsules of tellurium or pullulan. That is, by incorporating monosaccharide alcohols, more preferably D-manntol or D sorbitol into the capsule skin, the elution of the hard capsules is remarkably improved and the moldability is excellent. I found it. In addition, in the manufacture of hard-pressed capsules, the viscosity of the capsule preparation liquid is high, leading to a decrease in productivity.
  • sugar alcohols preferably monosaccharide alcohols
  • the gelling property is improved as the amount of the gelling agent used at the time of manufacturing the hard capsule is increased, so that the moldability of the capsule is improved while the solubility of the capsule is lowered.
  • sugar alcohols preferably monosaccharide alcohols, more preferably D-manntol and D-sorbitol are suitable. It has been found that the viscosity of the gel is lowered, the gelling property of the gelling agent is improved, and the effect is produced, which greatly contributes to the improvement of the capsule productivity. The present invention has been completed based on these findings.
  • a hard capsule containing a water-soluble cellulose ether or pullulan as a base of the capsule skin, characterized by containing sugar alcohols in the capsule skin;
  • a method for producing a hard capsule comprising immersing a pin in a solution containing water-soluble cellulose ethers or pullulan containing a sugar alcohol and a gelling agent, and drying the gel attached to the pin ,
  • the hard capsule of the present invention is excellent in moldability, and a hard capsule produced by filling the hard capsule with a medicine, food, health food, veterinary medicine, quasi drug, etc. Or, since it has excellent solubility during ingestion or handling, the effect of the filler can be quickly demonstrated in the body or outside the body to achieve the purpose.
  • FIG. 1 A schematic diagram of a process for producing a hard capsule of the present invention.
  • Step (1) shows a step of separating the body portion and the cap portion of the hard capsule.
  • Step (2) shows a filling step of filling the hard capsule body.
  • Step (3) shows a step of fitting the cap portion to the hard capsule body portion containing the filler.
  • Step (4) shows a step of sealing the fitted hard capsule with a sealing agent.
  • Step (5) shows a step of drying the sealed hard capsule.
  • FIG. 2 shows X-ray diffraction patterns of cast films obtained by putting a certain amount of the solutions of Example 2 and Comparative Example 1 in a petri dish and then drying at room temperature.
  • the present invention relates to a hard capsule having improved moldability and solubility, characterized in that a sugar alcohol is blended with a hard capsule base of water-soluble cellulose ethers or polysaccharide pullulan, and the hard capsule And a hard capsule comprising the hard capsule filled with contents.
  • Hard capsules of these water-soluble cellulose ethers can be produced by a known method capable of molding the capsule, but are produced according to a normal dating method (immersion molding method) (see: Patent Documents 1 to 3 above).
  • water-soluble cellulose ethers are dispersed and dissolved in water, alcohol or a mixture of alcohols, and sugar alcohol is added and dissolved in the water-soluble cellulose ether solution, and the resulting capsule soaking solution is used for capsule formation.
  • a pin can be dipped at a predetermined temperature, and then a capsule dipping solution adhering to the pin can be gelled to form a hard capsule.
  • a gelling agent and a gelling aid may be appropriately added.
  • colorants eg titanium oxide, bengara, blue No. 2, yellow No. 5 etc.
  • opacifiers titanium oxide etc.
  • fragrances eg., slip improvers, plasticizers etc.
  • water-soluble cellulose ethers or those having a preferable effect on the moldability and solubility of hard capsules of pullulan preferably water-soluble cellulose ethers or pullulan are used in an amorphous form.
  • Any sugar alcohol can be used as long as it can make the ether or pullulan amorphous.
  • monosaccharide alcohols are preferred, more preferably D-mannitol, D-sorbitol or a mixture thereof.
  • monosaccharide alcohols are sugar alcohols having 5 to 6 carbon atoms.
  • the mixing ratio of sugar alcohols in the capsule preparation liquid is generally about 0.5 to 10% by weight, preferably about 1 to 8% by weight, more preferably about 1.5 to 7.5% by weight. .
  • the amount of sugar alcohols is about 20 to 40% by weight, preferably about 17.5 to 35% by weight, more preferably about 15 to 30% by weight, based on the total solid content of the capsule skin. It is. If the amount is less than this amount, the water-soluble cellulose ethers or pullulan may not be made amorphous. On the other hand, if the amount is larger than this amount, the capsule cannot be molded, and even if it can be molded, the capsule strength may decrease, or white spots may appear on the appearance.
  • the “solid content of the entire capsule skin” is the weight excluding the solvent component (for example, purified water) of the capsule preparation liquid.
  • amorphous means that in the structure of the corresponding substance, the molecules are not regularly arranged but arranged in a disorderly manner.
  • a solid dispersion may or may not be formed.
  • the “solid dispersion” is a substance in a state where other solid components are uniformly dispersed and stabilized in the polymer carrier. The formation of an amorphous material and a solid dispersion can be confirmed by X-ray diffraction. When the material is made non-quality, the characteristic peak observed in crystallization often disappears.
  • water-soluble cellulose ethers used as capsule bases include methyl cellulose, hydroxypropino retino resenorelose, hydroxy ethino reseno relose, hydroxy methyl methyl cellulose, hydroxy ethyl cellulose, and hydroxypropyl cellulose.
  • hydroxyalkylalkylcellulose is preferable.
  • hydroxypropylmethylcellulose is more preferred and exemplified as a base.
  • the blending ratio of the water-soluble cell mouth ether in the capsule preparation liquid is generally about 5 to 30% by weight, preferably 7.5 to 25% by weight, more preferably 10 to 20% by weight.
  • blending of water-soluble cellulose ethers with respect to the solid content of the entire capsule skin Amount will range from about 65 to 95 weight 0/0, preferably from about 70 to 90 weight 0/0, more preferably to about 72.5 to 87.5 wt%. If the blending ratio is less than this, the capsule film becomes thin and the strength of the capsule may be lowered. On the other hand, if the blending ratio is higher than this, the solubility of the capsule may be lowered.
  • the gelling agent used in the production of the hard capsules of the water-soluble cellulose ethers is not particularly limited, but has a functional group capable of forming a salt such as a carboxyl group, a sulfate group, or an amino group. Any one that melts at 40 to 80 ° C. and solidifies the capsule at room temperature (about 25 to 50 ° C.) can be used.
  • examples of such gelling agents include polysaccharides and celluloses. Specific examples of polysaccharides include carrageenan, agar, starch, and mannan. Specific examples of celluloses include methylcellulose and hydroxypropylcellulose. , Hydroxypropyl methylcellulose, and the like are preferable.
  • Carrageenan, agar, starch, and mannan are preferable, and carrageenan, agar, and denpen are more preferable.
  • the starch include corn starch, potato starch, rice starch and wheat starch.
  • the gelling agent can be used alone or as a mixture of two or more.
  • the blending ratio of the gelling agent in the capsule preparation liquid is about 0.01 to: LO wt%, preferably about 0.025 to 5 wt%, more preferably about 0.03 to 3 wt%. It is. About 0.05 to 20.0% by weight, preferably about 0.075 to 10.0% by weight, more preferably about 0.1 to 5.0% by weight, based on the total solid content of the capsule skin . If the amount of the gelling agent is less than this blending amount, it may generally be difficult to form a capsule, and if it is more than this blending amount, the disintegration property of the capsule may be deteriorated.
  • a gelling aid for example, potassium ions, ammonium ions and the like can be appropriately added to improve gelling properties and improve moldability.
  • the mixing ratio of the gelling aid in the capsule preparation solution is about 0.05 to 0.6% by weight, preferably about 0.06 to 0.5% by weight, more preferably about 0.07 to 0.4%. % By weight.
  • hard capsules based on pullulan can be manufactured according to the description in JP-A-2000-202003. That is, a capsule-forming pin is immersed in a capsule preparation solution in which pullulan and a gelling agent are dissolved, and the capsule preparation solution adhering to the pin is gelled and dried on this pin.
  • pullulan is an a-1,6-linked natural polysaccharide with maltotriose obtained by culturing Aureobasidium Pul lulans, a kind of black yeast, using starch as a raw material. It has been known for a long time as an additive for cosmetics and the like, and commercially available products such as pullulan PI-20 (manufactured by Hayashibara Co., Ltd.) can be used.
  • the blending ratio of pullulan in the capsule preparation liquid is generally about 5 to 30% by weight, preferably 7.5 to 25% by weight, more preferably 10 to 20% by weight.
  • the amount of pullulan is about 65 to 95% by weight, preferably about 70 to 90% by weight, more preferably about 72.5 to 87.5% by weight, based on the total solid content of the capsule shell. If the blending ratio is less than this, the capsule film becomes thin, and the strength of the capsule may be lowered. On the other hand, if the blending ratio is larger than this, the solubility of the capsule may be lowered.
  • the gelling agent to be added to the pullulan hard capsule preparation liquid can be exemplified by the same gelling agents as the water-soluble cellulose ethers, and a substance that easily gels due to temperature change is preferred. More specifically, xanthan gum, locust bean gum, gellan gum, carrageenan, tamarind seed polysaccharide, pectin, curdlan, gelatin, fur celerane, agar, etc. It can also be used.
  • xanthan gum Z locust bean gum, dielan gum, and carrageenan are suitable for Punoreran.
  • the blending ratio of the gelling agent in the capsule preparation liquid is about 0.01 to 10% by weight, preferably about 0.025 to 5% by weight, more preferably about 0.03 to 3% by weight.
  • Gelling agent power If less than this amount, it is generally difficult to form capsules. If the amount is more than the amount of octopus, the disintegration property of the capsule may be deteriorated.
  • kappa carrageenan Kappa Ichiroku Laginan
  • water-soluble compounds that give potassium ions, ammonium ions, calcium ions as gelling aids,
  • salt potassium, salt ammonium, acetate acetate, salt calcium, etc. can be used.
  • Water-soluble compounds can be used.
  • water-soluble compounds that give sodium ions, potassium ions, calcium ions, magnesium ions as gelling aids such as sodium chloride sodium, salt potassium, salt ⁇ Calcium, magnesium sulfate and the like can be used, and organic acids and water-soluble salts thereof such as citrate or sodium taenoate can be used.
  • the blending ratio of the gelling aid in the capsule preparation liquid is about 0.05 to 0.6% by weight, preferably about 0.06 to 0.00. 5% by weight, more preferably about 0.07-0.4% by weight.
  • an appropriate amount of additives usually used for hard capsules such as colorants, opacifiers, fragrances, slip improvers, and plasticizers may be added.
  • the opaque agent titanium oxide is preferably used.
  • hydroxypropylmethylcellulose capsules in the present invention Preferable hydroxypropylmethylcellulose capsules in the present invention! /, The combination of ingredients is hydroxypropylmethylcellulose, kappa rugassin, potassium chloride, D-manntol and Z or D-sorbitol, and titanium oxide. May be added.
  • the amount of preparation of the capsule generally hydroxy propyl cellulose of about 5 to 30 wt%, kappa Ichiriki Raginan about 0.01 to 10 weight 0/0, potassium chloride of about 0.05 to 0.
  • hydroxypropylmethylcellulose about 7.5 to 25 wt%
  • kappa Ichiriki Raginan about 0.025 to 5 wt%
  • potassium chloride about 0.06 to 0 5 weight 0/0
  • D-Man - Toll and Z or D-sorbitol are about 1-8% by weight, if added with titanium dioxide, about 0.2-3% by weight
  • purified water is about 70-90% by weight.
  • hydroxypropyl methylcellulose about 10-20 weight 0/0, ⁇ -.
  • Carrageenan about 0.03 to 3 wt%, potassium chloride of about 0.07 to 0 4% by weight, D-Man two tall and Z or D- sorbitol approximately 1.5 to 7.5 weight 0/0, if added Caro titanium oxide, about 0.3 to 6 wt%, purified water is about 75 to 85 wt%.
  • the solid content in the capsule shell of hydroxypropylmethylcellulose capsules in the present invention is generally about 65 to 95% by weight of hydroxypropylmethylcellulose, about 0.05 to 20% by weight of Kappa lagonin, and potassium chloride. There about 0.05 to 20 wt%, D- Man - tall and Z or D- sorbitol from about 20 to 40 weight 0/0, if titanium oxide is added, about 0.1 to 10 wt% It is.
  • hydroxy propyl cellulose of about 70-90 weight 0/0, kappa Ichiriki Raginan about 0.075 to 10.0 wt 0/0, potassium chloride of about 0.075 to 10 weight 0/0, D - Man - tall and Z or D - sorbitol from about 17.5 to 35 wt%, if titanium oxide is added, is from 0.2 to 7.5 wt 0/0.
  • hydroxypropylmethyl cellulose of about 72.5 to 8 7.5 wt%, kappa Ichiriki Raginan about 0.1 to 5.0 wt%, potassium chloride of about 0.1 to 5.0 weight 0/0 , D- Man - tall and Z or D- sorbitol from about 15 to 30 weight 0/0, if the acid titanium is added, from about 0.3 to 6 wt%.
  • Preferable pullulan capsules in the present invention U the combination of ingredients is pullulan, kappa one laguinane, potassium chloride, D-manntol and Z or D-sorbitol, with addition of titanium oxide. It may be.
  • the amount of preparation of the capsule generally pullulan about 5-30 wt%, kappa Ichiriki Raginan about 0.01 to 10 wt%, salt I spoon potassium about 0.05 to 0.6 weight 0 / 0 , D-mannitol and Z or D-sorbitol are about 0.5 to: L0% by weight, about 0.1 to 5% by weight of titanium oxide, about 65% purified water ⁇ 95% by weight.
  • pullulan about 7.5 to 25 wt%, kappa Ichiriki Ragi one Nan about 0.025 to 5 weight 0/0, potassium chloride of about 0.06 to 0.5 weight 0/0, D- Cloak Lumpur and Z or D- sorbitol from about 1-8 weight 0/0, if the addition of titanium oxide, about 0.2 to 3 wt%, purified water is about 70 to 90 wt%. More preferably, pullulan about 10 to 20 wt%, kappa Ichiriki Raginan about 0.03 to 3 wt%, potassium chloride of about 0.07 to 0 4 wt 0/0, D-Man -. Tall and Z Or D-sorbitol is about 1.5 to 7.5% by weight; if acid-titanium is added, about 0.3 to 6% by weight; purified water is about 75 to 85% by weight.
  • the solid content in the capsule skin of the pullulan capsules according to the present invention is generally about 65 to 95% by weight of pullulan, about 0.05 to 20% by weight of ⁇ -carrageenan, and about 0.05 of potassium chloride. 20wt 0/0, D- Man - tall and Z or D- sorbitol from about 20 to 40 wt%, if titanium oxide is added, Ru about 0.1 to 10 wt% der. Preferably, pullulan about 70-90 weight 0/0 One force Raginan about 0.
  • 075- 10.0 wt kappa 0/0, potassium chloride of about 0.075 to 10 weight 0/0, D-Man - Tall and Z or D—sorbitol is about 17.5-35% by weight, and if titanium oxide is added, 0.2-7.5% by weight. More preferably pullulan about 72.5 to 87.5 weight 0/0, kappa Ichiriki Ruggie Nan about 0.1 to 5.0 wt%, potassium chloride of about 0.1 to 5.0 wt%, D -Mannitol and cocoon or D-sorbitol is about 15-30% by weight, and if titanium oxide is added, about 0.3-6% by weight.
  • the temperature at which the pin for forming the pullulan hard capsule is immersed is also appropriately selected.
  • the force is preferably about 30 to 80 ° C, particularly about 40 to 60 ° C.
  • the viscosity of the capsule preparation liquid during the pin immersion is about 100 to 10, OOOmPa-s (cps), more preferably 500 to 5000 mPa-s (cps). This viscosity is a value measured by a B-type rotational viscometer (20 ° C). If the viscosity is lower than this, there is a risk that the capsule film thickness will be thin due to less capsule raw material adhering to the capsule forming pin. If the viscosity is too high, it may be difficult to control the capsule shape in general. There is.
  • the gelling after the pins are pulled up is preferably performed by allowing to cool, but may be dried by heating to about 40 to 80 ° C after gelation.
  • FIG. 1 schematically shows a production process of the hard capsule and the hard capsule of the present invention.
  • the body part (2) and the cap part (1) of the hard capsule can be obtained.
  • the body part and cap part of the water-soluble cellulose derivative or pullulan hard capsule thus obtained are filled with the filler (3) through the filling tube (4), and then the body part is covered with the cap part.
  • the body part and the cap part are joined by fitting them together, so that the circle of the body part and the cap part is formed on the surface of the body part and the surface of the cap part with a constant width centered on the edge part of the cap part.
  • the fitting part can be sealed (5) by applying the band-sinole agent once to a plurality of times, preferably once or twice in the circumferential direction.
  • a hard capsule can be obtained by filling a filler (for example, pharmaceutical, food, health food) by a method known per se before sealing the fitting portion.
  • the fitting width where the outer circumference of the body part and the inner circumference of the cap part overlap is the distance in the axial direction of the capsule. About 4.5 to 6.5 mm for capsules and about 4.0 to 6. Omm for No. 4 capsules are generally preferred. Also, the sealing width is generally about 1.5-3. Omm for No. 3 capsule, and about 1.5-2.8 mm for No. 4 capsule!
  • the size of the hard capsule thus obtained includes 00, 0, 1, 2, 3, 4, 5, etc., but in the present invention! Can be manufactured.
  • Examples of the filler to be filled in the hard capsule include human or animal pharmaceuticals, foods, health foods, etc., and any one that does not dissolve or react with the hard capsule film of water-soluble cellulose ethers can be used.
  • the properties of the filler may be any of solid, semi-solid, crystalline, oily, solution and the like.
  • the hard pushell of the present invention is not only a container for oral administration of pharmaceuticals, foods, health foods, etc., but also a so-called quasi-drug for the purpose of disinfecting / cleaning dentures, glasses, contact lenses, etc. It can also be applied as a capsule for filling.
  • Peanut oil, corn oil, hydrogenated oil, paraffin oil, honey beeswax and the like, and fatty acids and derivatives thereof include stearic acid, palmitic acid, myristic acid, triethyl citrate, triacetin, and medium-chain fatty acid tridariseide.
  • an active substance such as a pharmaceutical may be dissolved in the liquid filling, but the active substance may be suspended in the liquid filling, or the liquid filling itself may be an active substance solution.
  • the liquid capsule When the liquid capsule is filled into the hard capsule of the present invention, it is necessary to seal the boundary between the hard capsule cap and the body. Sealing of hard capsules is carried out using a capsule filling and sealing machine known per se, such as the capsule filling and sealing machine or the capsule sealing machine (model name: HICAPSEAL 40/100, manufactured by Shionogi Qualicabus Co., Ltd.). Can. Further, like the liquid filler, the capsule of the present invention can be filled with the solid filler.
  • a capsule filling and sealing machine known per se, such as the capsule filling and sealing machine or the capsule sealing machine (model name: HICAPSEAL 40/100, manufactured by Shionogi Qualicabus Co., Ltd.). Can.
  • the capsule of the present invention can be filled with the solid filler.
  • Examples of the medicine filled in the hard capsule of the present invention include nourishing tonic health drugs, antipyretic analgesics, antipsychotics, anti-anxiety drugs, antidepressants, hypnotic sedatives, antispasmodics, central nervous system Drugs, cerebral metabolism improving agents, cerebral circulation improving agents, antiepileptic agents, sympathomimetic agents, gastrointestinal agents, antacids, antiulcer agents, antitussive expectorants, antiemetics, respiratory stimulants, bronchodilators, allergic agents , Dental and oral medicine, antihistamine, cardiotonic, arrhythmic agent, diuretic, antihypertensive agent, vasoconstrictor, coronary vasodilator, peripheral vasodilator, hyperlipidemia agent, biliary, antibiotic, chemical Therapeutic agent, antidiabetic agent, osteoporosis agent, antirheumatic drug, skeletal muscle relaxant agent, antipruritic agent, hormone agent, alkaloid narcotic
  • Nourishing tonic health drugs include, for example, vitamin A, vitamin D, vitamin E (such as acetic acid d—a-tocopherol), vitamin B1 (such as dibenzoylthiamine, fursultiamine hydrochloride), vitamin B2 ( Such as riboflavin butyrate), vitamin B6 (such as pyridoxine hydrochloride), vitamin C (such as ascorbic acid, sodium L-ascorbate), vitamin B12 (such as hydroxocobalamin acetate, cyanobaramin acetate), calcium, magnesium, This includes minerals such as iron, proteins, amino acids, oligosaccharides, and crude drugs.
  • vitamin A vitamin D
  • vitamin E such as acetic acid d—a-tocopherol
  • vitamin B1 such as dibenzoylthiamine, fursultiamine hydrochloride
  • vitamin B2 Such as riboflavin butyrate
  • vitamin B6 such as pyridoxine hydrochloride
  • vitamin C such as as
  • antipyretic analgesic anti-inflammatory drugs examples include Spirin, acetaminophen, ethenzamide, ibuprofen, diphenhydramine hydrochloride, cQ-chlorfelamine maleate, dihydrocodeine phosphate, nospower pin, methyl ephedrine hydrochloride, phenol propanolamine hydrochloride, caffeine, anhydrous caffeine, sera
  • antipyretic analgesic anti-inflammatory drugs include Spirin, acetaminophen, ethenzamide, ibuprofen, diphenhydramine hydrochloride, cQ-chlorfelamine maleate, dihydrocodeine phosphate, nospower pin, methyl ephedrine hydrochloride, phenol propanolamine hydrochloride, caffeine, anhydrous caffeine, sera
  • peptase, lysozyme chloride tolfenamic acid, mefenamic acid, diclofenac sodium, flufena
  • Examples of the psychotropic drug include chlorpromazine, reserpine and the like.
  • Examples of anti-anxiety drugs include alprazolam, chlordiazepoxide, diazepam and the like.
  • Examples of the antidepressant include imibramin, maprotiline hydrochloride, amphetamine and the like.
  • Examples of the hypnotic sedative include estazolam, nitrazebam, diazebam, perlapine, sodium phenobarbital and the like.
  • Antispasmodic agents include, for example, scopolamine hydrobromide, diphenhydramine hydrochloride, papaverine hydrochloride, and the like.
  • Examples of central neuropathic drugs include citicoline.
  • Examples of the brain metabolism improving agent include meclofenixate hydrochloride.
  • Examples of the cerebral circulation improving agent include vinpocetine.
  • Antiepileptic agents include, for example, fatin, strong rubamazepine and the like.
  • Examples of sympathomimetic agents include isoproterenol hydrochloride.
  • Gastrointestinal drugs include, for example, healthy stomach antiseptics such as diastase, sugar-containing pepsin, funnel extract, cellulase AP3, lipase AP, keihi oil, intestinal agents such as salt berberine, resistant lactic acid bacteria, and bifidobacteria. included.
  • Examples of the antacid include magnesium carbonate, sodium hydrogen carbonate, magnesium aluminate metasilicate, synthetic hydrotalcite, precipitated calcium carbonate, magnesium oxide and the like.
  • Examples of the anti-ulcer agent include lansoprazole, omebrazole, rabeprazole, famotidine, cimetidine, latidine hydrochloride and the like.
  • Examples of the antitussive expectorant include cloperastine hydrochloride, dextromelt fan hydrobromide, theophylline, potassium guaiacol sulfonate, guaifenesin, and codin phosphate.
  • Examples of the antiemetic include diphe-dol hydrochloride, metocloblamide and the like.
  • Examples of the respiration promoting agent include levalorphan tartrate.
  • Examples of bronchodilators include theophylline and salbutamol sulfate.
  • Allergic drugs and Examples include amlexanox and seratrodast.
  • Examples of the dental and oral medicine include oxytetracycline, triamcinolone acetonide, chlorhexidine hydrochloride, lidocaine and the like.
  • Examples of the antihistamine include diphenhydramine hydrochloride, promethazine, isothipentyl hydrochloride, dl-chlorfelamin maleate, and the like.
  • Examples of the cardiotonic agent include caffeine and digoxin.
  • Examples of the arrhythmic agent include prokinamide hydrochloride, propranolol hydrochloride, pindolol and the like.
  • Examples of diuretics include isosorbide, furosemide, and hydrothiazide thiazide.
  • antihypertensive agent examples include delapril hydrochloride, captopril, hydralazine hydrochloride, labetalol hydrochloride, iliapine hydrochloride, candesartan cilexetil, methyldono, and perindopril elpmine.
  • vasoconstrictor examples include fe-refrin hydrochloride and the like.
  • Examples of the coronary vasodilator include carbochromene hydrochloride, molsidomine, and perapamil hydrochloride.
  • Examples of peripheral vasodilators include cinnarizine.
  • Examples of the hyperlipidemia agent include cerivastatin sodium, sympastatin, pravastatin sodium, atorvastatin calcium hydrate and the like.
  • Examples of the astringent include dehydrocholic acid and trepeptone.
  • Antibiotics include, for example, cefemine such as cephalexin, cefaclor, amoxicillin, pipmecillin hydrochloride, cefothiam hexetyl, cephadoxyl, cefixime, cefditoren poxyxil, cefteram pivoxil, cefpodoximiproxetil, ampicillin, Synthetic antibacterial agents such as cyclacin, nalidixic acid, enoxacin, monobatams such as carmonam sodium, penems, and rubapenem antibiotics.
  • cefemine such as cephalexin, cefaclor, amoxicillin, pipmecillin hydrochloride, cefothiam hexetyl, cephadoxyl, cefixime, cefditoren poxyxil, cefteram pivoxil, cefpodoximiproxetil, ampicillin
  • Synthetic antibacterial agents such as cyclacin, n
  • Examples of the chemotherapeutic agent include sulfamethizole.
  • Examples of the antidiabetic agent include tolptamide, voglibose, pioglitazone hydrochloride, darifenclamide, and trodaridazone.
  • Examples of the osteoporosis agent include ibriflavone.
  • Examples of skeletal muscle relaxants include metocarbamol.
  • Examples of the antispasmodic agent include methalizine hydrochloride and dimenhydrinate.
  • Antirheumatic drugs include mesotrexate and bucillamine.
  • Hormonal agents include, for example, Rioti-Natrium, Dexamethasone Sodium Phosphate, Pred-Zolone, Oxendron, Leuproacetate Examples include relin.
  • Alkaloid narcotics include opium, morphine hydrochloride, tocone, oxycodone hydrochloride, opium alkaloid hydrochloride, cocaine hydrochloride, and the like.
  • Examples of the sulfa drugs include sulfisomidine and sulfamethizole.
  • anti-gout drugs include alopurinol and colchicine.
  • Examples of the blood coagulation inhibitor include dicumarol.
  • Examples of the antineoplastic agent include 5-fluorouracil, uracil, mitomycin and the like.
  • Examples of the health food filled in the hard capsule of the present invention include Coenzyme Q10, royal jelly, propolis, psyllium, maca extract, agaritas and the like.
  • These medicaments can be used alone or in combination with other medicaments.
  • these medicines are filled with known appropriate amounts determined as appropriate according to the disease, age, etc. of the patient.
  • Filling of the filling into the hard capsule of the present invention is performed by a known capsule filling machine such as a fully automatic capsule filling machine (model name: LIQFILsuper80 / 150, manufactured by Shionogi Qualicaps Co., Ltd.), capsule filling and sealing machine ( Model name: LIQFILsuperFS, manufactured by Shionogi Qualicabus Co., Ltd.) and the like.
  • a known capsule filling machine such as a fully automatic capsule filling machine (model name: LIQFILsuper80 / 150, manufactured by Shionogi Qualicaps Co., Ltd.), capsule filling and sealing machine ( Model name: LIQFILsuperFS, manufactured by Shionogi Qualicabus Co., Ltd.) and the like.
  • the water-soluble cellulose ethers or pullulan hard capsules of the present invention have characteristics such as excellent moldability and elution and can be industrially produced.
  • the solubility of hard capsules containing water-soluble cellulose ethers or pullulan as the main component of the capsule skin should be improved by adding D-manntool and Z or D-sorbitol into the capsule skin. Can do.
  • the opening time of the HPMC capsule of the present invention is preferably 5 minutes or less.
  • the opening time of the pullulan capsule of the present invention is preferably 10 minutes or less.
  • the HPMC capsule of the present invention when acetaminophen is filled as a capsule-filled drug and a dissolution test is conducted with the second solution of the Japanese Pharmacopoeia based on the 15th revised Japanese Pharmacopoeia paddle method (with sinker), the HPMC capsule of the present invention If present, the pullulan capsule of the present invention is preferred to elute more than 55% of acetaminophen 10 minutes after the start of the test and 80% or more after 20 minutes. If present, it is preferable that 25% or more of the aminoaminophene elute after 10 minutes from the start of the test and 70% or more after 20 minutes.
  • the 4 wt% carrageenan aqueous solution was added to the HPMC dispersion so that the carrageenan concentration was 0.06 wt%. This was transferred to a pressure reducing desiccator, depressurized at 55 ° C for 1 hour or longer, and degassed. After defoaming, it was stored in an oven at 55 ° C for 1 day.
  • the HPMC dispersion thus obtained was poured into an acrylic container that had been preliminarily kept at 55 ° C., and a pin bar for capsule production was immersed therein. After pulling out the pin bar from the above dispersion, it was subjected to aeration drying at room temperature for 2 hours to obtain an HPMC capsule.
  • Example 4 [0052] HPMC (15 wt 0/0), D-Man - Thor (2 wt 0/0), D-sorbitol (3 wt 0/0), .kappa.-carrageenan (0.06 wt%), Shioi ⁇ No. 3 capsules were prepared in the same manner as in Example 1 using potassium (0.10% by weight) and purified water (79.84% by weight).
  • Example No. 3 capsules were prepared in the same manner as in 1.
  • Opening test was performed using the hard capsules manufactured in Examples 1 to 4 and Examples 5 to 6 of the present invention and the hard capsules of Comparative Examples 1 and 2. Opening test, ⁇ Seth ⁇ amino phen (20 wt 0/0), after filling of lactose (70 wt 0/0) and croscarmellose composition consisting of sodium (10 wt 0/0) a (LOOmg) in each capsule Based on the 15th revised Japanese Pharmacopoeia paddle method (with sinker), the second solution was used as the test solution. The opening time was confirmed visually.
  • the HPMC hard capsule obtained in Example 1 of the present invention has a significantly improved dissolution property with a shorter disintegration time than the standard HPMC hard capsule of the comparative example.
  • the pullulan hard capsule obtained in Example 6 of the present invention has a dissolution property with a shorter disintegration time than the pullulan hard capsule of Comparative Example 2 without sugar alcohol in the coating. was significantly improved.
  • HPMC or pullulan as a hard capsule base, add 19.17% by weight of various saccharides to the entire capsule skin, and then form a capsule soaked solution with additives to form an HPMC hard capsule.
  • the capsule composition is shown in Table 4 below.
  • surface shows weight%.
  • Table 5 below shows the evaluation of the moldability of the hard capsule having the above composition.
  • HPMC hard capsules or pullulan hard capsules manufactured by adding D-mann-tol or D-sorbitol to the entire capsule skin at a solid content of 19.17% by weight. Nos. 1, 2, 4, 5) were confirmed to have no problem with capsule moldability, as no cracks were seen when peeling from the capsule forming pin. It was. As for the appearance of Capsule 36, white spots were seen on the capsule surface. On the other hand, the appearance of Capsule 1 2 4 5 did not have white spots on the capsule surface, and the appearance was almost the same as that of normal HPMC hard capsules containing no sugar allyl.
  • HPMC is used as a hard capsule base, and various saccharides are added in a solid amount of 15.11% by weight to the entire capsule skin, and a composition containing the additives is molded, and then HPMC hard capsules are prepared as usual. Manufactured according to Each capsule composition is shown in Table 6 below. The numerical values in the table indicate% by weight.
  • Table 7 below shows the evaluation of the moldability of the hard capsule having the above composition.
  • Example 2 The solutions of Example 2 and Comparative Example 1 were placed in a petri dish and then dried at room temperature to prepare a cast film.
  • the film was X-ray diffracted (see Figure 2).
  • the hard capsule according to the present invention is useful as a container for oral administration of pharmaceuticals, foods, health foods, veterinary drugs, quasi drugs and the like.

Abstract

La présente invention décrit une gélule dure obtenue en ajoutant un polyol sucré à un matériau de base pour gélules dures tel qu'un éther de cellulose hydrosoluble ou un pullulane, ceci afin d'améliorer sa solubilité et sa facilité de moulage. La présente invention décrit également un procédé de production de la gélule dure, ainsi qu'une préparation de type gélule dure comprenant la gélule dure et un médicament, un aliment, un alicament, un médicament vétérinaire ou un produit cosmétique contenant un médicament, encapsulé dans la gélule dure.
PCT/JP2006/301645 2005-02-03 2006-02-01 Gélule dure de solubilité améliorée WO2006082842A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2007501586A JPWO2006082842A1 (ja) 2005-02-03 2006-02-01 溶解性が改善された硬カプセル

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2005028263 2005-02-03
JP2005-028263 2005-02-03

Publications (1)

Publication Number Publication Date
WO2006082842A1 true WO2006082842A1 (fr) 2006-08-10

Family

ID=36777226

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2006/301645 WO2006082842A1 (fr) 2005-02-03 2006-02-01 Gélule dure de solubilité améliorée

Country Status (2)

Country Link
JP (1) JPWO2006082842A1 (fr)
WO (1) WO2006082842A1 (fr)

Cited By (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008099835A1 (fr) * 2007-02-15 2008-08-21 Qualicaps Co., Ltd. Bande de soudage pour capsules dures contenant du peg encapsulé
JP2009183563A (ja) * 2008-02-07 2009-08-20 Asahi Kasei Corp 人工授精材
JP2010523594A (ja) * 2007-04-05 2010-07-15 ユニバーシティ・オブ・カンザス プルランを含む速溶性医薬組成物
WO2014018279A1 (fr) 2012-07-23 2014-01-30 Dow Global Technologies Llc Composition de film pour des enveloppes de capsule dure
WO2014017756A1 (fr) * 2012-07-23 2014-01-30 삼성정밀화학(주) Composition aqueuse pour la préparation d'une capsule dure, son procédé de préparation, capsule dure et procédé de recyclage des déchets de capsule dure
JP2014502629A (ja) * 2011-01-11 2014-02-03 キャプシュゲル・ベルジウム・エヌ・ヴィ 新しい硬カプセル
US8900629B2 (en) 2007-04-05 2014-12-02 University Of Kansas Rapidly dissolving pharmaceutical compositions comprising pullulan
KR20150078673A (ko) * 2013-12-31 2015-07-08 삼성정밀화학 주식회사 경질 캡슐용 수성 조성물 및 이를 사용하여 제조된 경질 캡슐
KR20150078675A (ko) * 2013-12-31 2015-07-08 삼성정밀화학 주식회사 경질 캡슐용 수성 조성물 및 이를 사용하여 제조된 경질 캡슐
KR20150078674A (ko) * 2013-12-31 2015-07-08 삼성정밀화학 주식회사 경질 캡슐용 수성 조성물 및 이를 사용하여 제조된 경질 캡슐
US20170349342A1 (en) * 2016-06-06 2017-12-07 The Procter & Gamble Company Squeezable closures
USD835993S1 (en) 2016-07-18 2018-12-18 The Procter & Gamble Company Container with lid
JP6487092B1 (ja) * 2018-01-19 2019-03-20 株式會▲社▼ 瑞興 熱ゲル化ヒプロメロースハードカプセルの製造方法
EP3479821A1 (fr) * 2017-11-07 2019-05-08 Suheung Co., Ltd Procédé de fabrication de capsules dures de pullulane ayant des propriétés de film améliorées
CN109745296A (zh) * 2017-11-02 2019-05-14 浙江华光胶囊股份有限公司 一种胶囊及其制备方法
EP3549578A1 (fr) * 2018-04-06 2019-10-09 Bio Minerals N.V. Formulation d'acide silicique et son utilisation
US10463625B2 (en) 2012-05-02 2019-11-05 Capsugel Belgium Nv Bulk enteric capsule shells
US10676257B2 (en) 2016-06-06 2020-06-09 The Procter & Gamble Company Container systems with a squeeze-and-turn closure
US10793687B2 (en) 2012-12-05 2020-10-06 Lotte Fine Chemical Co., Ltd. Hard capsule having improved thickness uniformity
US10813886B2 (en) 2013-11-04 2020-10-27 Capsugel Belgium Nv Methods and systems for improved bioavailability of active pharmaceutical ingredients including esomeprazole
US11319566B2 (en) 2017-04-14 2022-05-03 Capsugel Belgium Nv Process for making pullulan
WO2022244713A1 (fr) * 2021-05-18 2022-11-24 ロンザ株式会社 Capsule dure non gélatineuse et sa méthode de production
US11576870B2 (en) 2017-04-14 2023-02-14 Capsugel Belgium Nv Pullulan capsules
US11878031B2 (en) 2018-10-05 2024-01-23 Bio Minerals N.V. Silicic acids for use in the treatment of periodontitis

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6310644A (ja) * 1986-05-05 1988-01-18 ワ−ナ−・ランバ−ト・カンパニ− 澱粉をベ−スとする配合物
JP2002525412A (ja) * 1998-09-30 2002-08-13 ワーナー−ランバート・カンパニー 変性デンプン膜組成物
EP1258242A1 (fr) * 2001-05-15 2002-11-20 Swiss Caps Rechte und Lizenzen AG Procédé de fabriaction de corps moulés, notamment de capsules molles
JP2003125714A (ja) * 2001-10-29 2003-05-07 Ina Food Ind Co Ltd カプセル基材及びそれからなるカプセル、並びにカプセル基材の製造方法
JP2004167084A (ja) * 2002-11-21 2004-06-17 Ina Food Ind Co Ltd ソフトカプセル皮膜、その原料及びソフトカプセル
WO2004062650A2 (fr) * 2003-01-08 2004-07-29 Swiss Caps Rechte Und Lizenzen Ag Formulations de produit de remplissage
WO2004073692A1 (fr) * 2003-02-18 2004-09-02 Yamashita, Shinji Capsule dure de medicament peu hydrosoluble
JP2004534023A (ja) * 2001-05-10 2004-11-11 クロダ・インターナショナル・パブリック・リミテッド・カンパニー ゼラチン代用物
JP2004315466A (ja) * 2003-04-18 2004-11-11 Sansho Pharmaceutical Co Ltd カプセル用皮膜組成物
JP2006016372A (ja) * 2004-07-05 2006-01-19 Shionogi Qualicaps Co Ltd 腸溶性硬カプセル剤

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6310644A (ja) * 1986-05-05 1988-01-18 ワ−ナ−・ランバ−ト・カンパニ− 澱粉をベ−スとする配合物
JP2002525412A (ja) * 1998-09-30 2002-08-13 ワーナー−ランバート・カンパニー 変性デンプン膜組成物
JP2004534023A (ja) * 2001-05-10 2004-11-11 クロダ・インターナショナル・パブリック・リミテッド・カンパニー ゼラチン代用物
EP1258242A1 (fr) * 2001-05-15 2002-11-20 Swiss Caps Rechte und Lizenzen AG Procédé de fabriaction de corps moulés, notamment de capsules molles
JP2003125714A (ja) * 2001-10-29 2003-05-07 Ina Food Ind Co Ltd カプセル基材及びそれからなるカプセル、並びにカプセル基材の製造方法
JP2004167084A (ja) * 2002-11-21 2004-06-17 Ina Food Ind Co Ltd ソフトカプセル皮膜、その原料及びソフトカプセル
WO2004062650A2 (fr) * 2003-01-08 2004-07-29 Swiss Caps Rechte Und Lizenzen Ag Formulations de produit de remplissage
WO2004073692A1 (fr) * 2003-02-18 2004-09-02 Yamashita, Shinji Capsule dure de medicament peu hydrosoluble
JP2004315466A (ja) * 2003-04-18 2004-11-11 Sansho Pharmaceutical Co Ltd カプセル用皮膜組成物
JP2006016372A (ja) * 2004-07-05 2006-01-19 Shionogi Qualicaps Co Ltd 腸溶性硬カプセル剤

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ABSTRACT & RESEARCH DISCLOSURE, vol. 332, 1991, pages 908 *
DATABASE CAPLUS [online] XP002999967, accession no. STN Database accession no. (1992:257752) *

Cited By (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5489471B2 (ja) * 2007-02-15 2014-05-14 クオリカプス株式会社 Ｐｅｇ充填硬質カプセル剤のバンドシール
US9925719B2 (en) 2007-02-15 2018-03-27 Qualicaps Co., Ltd. Bandseal for PEG-filled hard capsule
WO2008099835A1 (fr) * 2007-02-15 2008-08-21 Qualicaps Co., Ltd. Bande de soudage pour capsules dures contenant du peg encapsulé
US9314966B2 (en) 2007-02-15 2016-04-19 Qualicaps Co., Ltd. Bandseal for PEG-filled hard capsule
JP2010523594A (ja) * 2007-04-05 2010-07-15 ユニバーシティ・オブ・カンザス プルランを含む速溶性医薬組成物
US8900629B2 (en) 2007-04-05 2014-12-02 University Of Kansas Rapidly dissolving pharmaceutical compositions comprising pullulan
JP2009183563A (ja) * 2008-02-07 2009-08-20 Asahi Kasei Corp 人工授精材
JP2014502629A (ja) * 2011-01-11 2014-02-03 キャプシュゲル・ベルジウム・エヌ・ヴィ 新しい硬カプセル
US10130587B2 (en) 2011-01-11 2018-11-20 Capsugel Belgium Nv Hard capsules
US10568839B2 (en) 2011-01-11 2020-02-25 Capsugel Belgium Nv Hard capsules
US10463625B2 (en) 2012-05-02 2019-11-05 Capsugel Belgium Nv Bulk enteric capsule shells
US10525010B2 (en) 2012-05-02 2020-01-07 Capsugel Belgium Nv Aqueous dispersions of controlled release polymers and shells and capsules thereof
US10898440B2 (en) 2012-05-02 2021-01-26 Capsugel Belgium Nv Bulk enteric capsule shells
CN104487058A (zh) * 2012-07-23 2015-04-01 三星精密化学株式会社 用于制备硬胶囊的含水组合物、其制备方法、硬胶囊及用于回收硬胶囊废料的方法
US11312878B2 (en) 2012-07-23 2022-04-26 Lotte Fine Chemical Co., Ltd. Aqueous composition for preparing hard capsule, preparation method therefor, hard capsule, and method for recycling hard capsule scraps
WO2014017756A1 (fr) * 2012-07-23 2014-01-30 삼성정밀화학(주) Composition aqueuse pour la préparation d'une capsule dure, son procédé de préparation, capsule dure et procédé de recyclage des déchets de capsule dure
WO2014018279A1 (fr) 2012-07-23 2014-01-30 Dow Global Technologies Llc Composition de film pour des enveloppes de capsule dure
US10793687B2 (en) 2012-12-05 2020-10-06 Lotte Fine Chemical Co., Ltd. Hard capsule having improved thickness uniformity
US10813886B2 (en) 2013-11-04 2020-10-27 Capsugel Belgium Nv Methods and systems for improved bioavailability of active pharmaceutical ingredients including esomeprazole
KR102161001B1 (ko) * 2013-12-31 2020-09-29 롯데정밀화학 주식회사 경질 캡슐용 수성 조성물 및 이를 사용하여 제조된 경질 캡슐
KR20150078673A (ko) * 2013-12-31 2015-07-08 삼성정밀화학 주식회사 경질 캡슐용 수성 조성물 및 이를 사용하여 제조된 경질 캡슐
KR20150078675A (ko) * 2013-12-31 2015-07-08 삼성정밀화학 주식회사 경질 캡슐용 수성 조성물 및 이를 사용하여 제조된 경질 캡슐
KR102199595B1 (ko) * 2013-12-31 2021-01-07 롯데정밀화학 주식회사 경질 캡슐용 수성 조성물 및 이를 사용하여 제조된 경질 캡슐
KR102199596B1 (ko) * 2013-12-31 2021-01-07 롯데정밀화학 주식회사 경질 캡슐용 수성 조성물 및 이를 사용하여 제조된 경질 캡슐
KR20150078674A (ko) * 2013-12-31 2015-07-08 삼성정밀화학 주식회사 경질 캡슐용 수성 조성물 및 이를 사용하여 제조된 경질 캡슐
WO2015102196A1 (fr) * 2013-12-31 2015-07-09 삼성정밀화학 주식회사 Composition aqueuse pour gélule, et gélule produite au moyen de celle-ci
WO2015102197A1 (fr) * 2013-12-31 2015-07-09 삼성정밀화학 주식회사 Composition aqueuse pour gélule et gélule fabriquée à partir de celle-ci
JP2017501190A (ja) * 2013-12-31 2017-01-12 ロッテ精密化學株式会社ＬＯＴＴＥ Ｆｉｎｅ Ｃｈｅｍｉｃａｌ Ｃｏ．，Ｌｔｄ． 硬質カプセル用水性組成物及びこれを使用して製造された硬質カプセル
WO2015102198A1 (fr) * 2013-12-31 2015-07-09 삼성정밀화학 주식회사 Composition aqueuse pour gélule, et production de gélule utilisant celle-ci
US10676257B2 (en) 2016-06-06 2020-06-09 The Procter & Gamble Company Container systems with a squeeze-and-turn closure
US20170349342A1 (en) * 2016-06-06 2017-12-07 The Procter & Gamble Company Squeezable closures
USD893304S1 (en) 2016-07-18 2020-08-18 The Procter & Gamble Company Lid for container
USD835993S1 (en) 2016-07-18 2018-12-18 The Procter & Gamble Company Container with lid
US11878079B2 (en) 2017-04-14 2024-01-23 Capsugel Belgium Nv Pullulan capsules
US11576870B2 (en) 2017-04-14 2023-02-14 Capsugel Belgium Nv Pullulan capsules
US11319566B2 (en) 2017-04-14 2022-05-03 Capsugel Belgium Nv Process for making pullulan
CN109745296A (zh) * 2017-11-02 2019-05-14 浙江华光胶囊股份有限公司 一种胶囊及其制备方法
EP3479821A1 (fr) * 2017-11-07 2019-05-08 Suheung Co., Ltd Procédé de fabrication de capsules dures de pullulane ayant des propriétés de film améliorées
CN109745297A (zh) * 2017-11-07 2019-05-14 株式会社瑞兴 制造具有改善的膜性能的普鲁兰多糖硬胶囊的方法
CN109745297B (zh) * 2017-11-07 2021-03-09 株式会社瑞兴 制造具有改善的膜性能的普鲁兰多糖硬胶囊的方法
JP6487092B1 (ja) * 2018-01-19 2019-03-20 株式會▲社▼ 瑞興 熱ゲル化ヒプロメロースハードカプセルの製造方法
JP2019127477A (ja) * 2018-01-19 2019-08-01 株式會▲社▼ 瑞興 熱ゲル化ヒプロメロースハードカプセルの製造方法
EP3549578A1 (fr) * 2018-04-06 2019-10-09 Bio Minerals N.V. Formulation d'acide silicique et son utilisation
WO2019193200A1 (fr) * 2018-04-06 2019-10-10 Name: Bio Minerals N.V. Formulation d'aide silicique et son utilisation
US11878031B2 (en) 2018-10-05 2024-01-23 Bio Minerals N.V. Silicic acids for use in the treatment of periodontitis
WO2022244713A1 (fr) * 2021-05-18 2022-11-24 ロンザ株式会社 Capsule dure non gélatineuse et sa méthode de production

Also Published As

Publication number Publication date
JPWO2006082842A1 (ja) 2008-08-07

Similar Documents

Publication Publication Date Title
WO2006082842A1 (fr) Gélule dure de solubilité améliorée
JP5539503B2 (ja) 不快味を効果的に隠蔽した経口用速溶フィルム
RU2445977C2 (ru) Водорастворимые пленки, содержащие маловязкие альгинаты
US6432442B1 (en) Chewable product
WO2006070578A1 (fr) Bande de fermeture etanche pour gelule dure
JPH0213350A (ja) シユガーレスペクチンデリバリーシステム
JP2006016372A (ja) 腸溶性硬カプセル剤
TWI539976B (zh) 腸溶硬膠囊之組合物與使用此組合物所得之腸溶硬膠囊
AU2015289150B2 (en) Orodispersible film
CN110302144B (zh) 一种缓释型双层口腔溃疡膜及其制备方法
EP1757310A1 (fr) Capsule dure modifiée en surface et de solubilité renforcée
JP4364869B2 (ja) 咀嚼性カプセルの製造方法
JP2002275054A (ja) 易服用性固形製剤
JPS5924964B2 (ja) 徐放性製剤
JP5455203B2 (ja) フィルム製剤およびその製造方法
JP2001302500A (ja) 薬物の口用製剤
WO2021145296A1 (fr) Capsule dure contenant un dérivé de cellulose comme matériau de base et présentant une résistance mécanique et une perméabilité à l'oxygène améliorées
TWI820673B (zh) 布瑞哌唑口溶膜組合物、其製備方法及用途
JP2002330708A (ja) 可食性フィルム、包装食品、及び抗菌剤
US20180318228A1 (en) Method for a slow release of drugs from orally dissolving capsules
CN102485216A (zh) 一种药品爽口片
CN110833579B (zh) 一种防止固体食品或药品变色的包衣组合物及其应用
CN205411710U (zh) 含多单位载体的固态软式口溶锭
JP2023119660A (ja) 錠剤用基材、錠剤の崩壊促進用組成物、口腔用錠剤の食感および／または食味改良用組成物ならびに錠剤の製造方法
CN107952063A (zh) 降钙素片及其制备方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2007501586

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06712788

Country of ref document: EP

Kind code of ref document: A1

WWW Wipo information: withdrawn in national office

Ref document number: 6712788

Country of ref document: EP